Biomarkers have been causing a paradigm shift in how HCPs treat patients for some time – now they are bringing the pharma industry a new gold standard for clinical research.
Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’
More so now than ever, the inclusion of more diverse, and often more relevant, study populations is gathering momentum within the clinical trial community.
